DePuy Hip Replacement Products and Global Market Position
DePuy Orthopaedics, a subsidiary of Johnson & Johnson, designs and sells hip replacement systems including the ASR XL Acetabular System and the Pinnacle family. Johnson & Johnson reported total orthopaedics sales of about $27.1 billion for fiscal year 2023, with DePuy Synthes representing a major portion of that segmenthttps://www.forbes.com/sites/forbesbusinesscouncil/2024/01/10/johnson-johnson-reports-2023-revenue-and-earnings/. The ASR XL system was subject to a global recall in August 2010 after early failure rates exceeded initial projections, with regulatory agencies in multiple countries issuing safety communications.
In the United States, the FDA classifies hip implants as Class III devices requiring premarket approval, and DePuy has faced multiple warning letters and inspections over manufacturing and reporting practiceshttps://www.fda.gov/medical-devices/medical-device-safety/medical-device-safety-communications. Industry analysts rank DePuy among the leading global hip implant manufacturers alongside Stryker, Zimmer Biomet, and Smith & Nephew, with market share data updated annually by organizations such as the American Academy of Orthopaedic Surgeons and IQVIA.
DePuy Hip Replacement Litigation, Settlements, and Compensation
Thousands of patients filed personal injury and product liability lawsuits against DePuy and Johnson & Johnson after the ASR recall, alleging metallosis, dislocation, and tissue damage from metal-on-metal debris. In 2013, Johnson & Johnson agreed to pay approximately $2.5 billion to settle thousands of ASR hip replacement lawsuits in the United States, with individual payouts varying based on revision surgery costs and injury severity.
Beyond the ASR litigation, DePuy has faced additional claims related to other hip systems, including Pinnacle implants with metal-on-metal liners, with plaintiffs alleging elevated metal ion levels and early implant failurehttps://www.sec.gov/edgar/search/#/companyName=Johnson%20&%20Johnson&CIK=0000018163&type=10-K&dateb=&owner=include&count=40&search_text=&action=getcompany. Courts have allowed claims for medical expenses, lost wages, and pain and suffering, and some verdicts have included punitive damages when plaintiffs presented evidence of inadequate testing or delayed warnings.
Patient Outcomes, Revision Rates, and Current Regulatory Status
Registry data from the Australian Orthopaedic Association and the UK National Joint Registry show that metal-on-metal hip systems, including the DePuy ASR, had higher revision rates compared with ceramic and polyethylene bearing surfaces within five years of implantation. Revision surgery typically involves removing the failed implant, addressing damaged bone and soft tissue, and inserting a new hip system, with recovery times and outcomes depending on patient age, bone quality, and surgical technique.
Regulatory agencies continue to monitor post-market safety data for hip implants, and manufacturers must report adverse events through systems such as the FDA's Manufacturer and User Facility Device Experience database